Max Healthcare Q3 FY26: Sustained Growth Amidst Seasonal Headwinds

Max Healthcare Institute Limited, a prominent player in India's healthcare sector, has reported a robust performance for the third quarter and nine months ended December 31, 2025. Despite navigating seasonal softness and temporary external factors, the company demonstrated consistent growth across key financial and operational metrics. The Network's gross revenue for Q3 FY26 climbed to ₹2,608 crore, marking a solid 10% year-on-year increase. This growth was primarily fueled by an increase in Occupied Bed Days (OBDs). Operating EBITDA for the Network stood at ₹648 crore, reflecting a 4% year-on-year growth, while Profit After Tax (PAT) rose by 9% year-on-year to ₹344 crore, even after accounting for exceptional items. This quarter marks Max Healthcare's 21st consecutive quarter of year-on-year growth, underscoring its resilience and strategic execution in a dynamic market.

The company's performance was influenced by a mix of factors, including a temporary disruption in cashless services with standalone health insurers, which has since been restored. Additionally, the discontinuation of certain high-value patented chemotherapy drugs due to restrictive CGHS pricing guidelines and a GST rate change impacted margins. However, the operationalization of new brownfield beds at facilities like MSSH Mohali and Nanavati Max, which are already delivering accretive EBITDA margins, provided a significant boost. The management noted that the incremental bed capacity at these locations is already EBITDA and margin accretive, contributing positively to the overall financial health.

Strategic Expansion and Operational Excellence

Max Healthcare continues its aggressive expansion strategy, focusing on both brownfield and greenfield projects to enhance its bed capacity and market reach. A significant development in Q3 FY26 was the execution of a Share Purchase Agreement for the staggered acquisition of a 100% equity stake in Yerawada Properties Pvt. Ltd. (YPPL). This acquisition is aimed at developing a ~450-bed hospital in Pune, expected to be commissioned by 2030, marking MHIL's fourth facility in Western India. This move highlights the company's commitment to expanding its geographic footprint and tapping into new growth markets.

Several brownfield expansion projects are also nearing completion or have recently been commissioned. At MSSH Mohali, 53 beds out of a proposed 160-bed brownfield tower have been commissioned, with the balance expected by February end. These beds are already operating at a 46-bed occupancy and delivering an impressive EBITDA margin of ~39%. Similarly, Nanavati Max has operationalized 63 beds out of a 280-bed brownfield tower, achieving a 45-bed occupancy and an EBITDA margin of ~31%, with the remaining beds slated for commissioning by March end. A new 400-bed brownfield tower at Max Smart is also expected to be commissioned by February end in a phased manner, upon receipt of regulatory approvals. The Board also approved the brownfield expansion of the existing MSSH Dwarka facility to include 260 additional beds, increasing its total capacity to 560 beds.

Digital Initiatives and Patient Care

Beyond physical expansion, Max Healthcare is leveraging digital initiatives to drive revenue and enhance patient experience. Digital revenue from online marketing activities, web-based appointments, and digital lead management reached ₹803 crore in Q3 FY26, accounting for approximately 31% of overall revenue. Website traffic during the quarter grew by 44% year-on-year, crossing 71 lakh sessions. The company's strategic business units, Max Lab and Max@Home, continue to deliver steady growth. Max Lab reported a revenue of ₹47 crore, a 13% year-on-year growth, offering services across 60+ cities. Max@Home's revenue grew by 23% year-on-year to ₹68 crore, driven by physio & rehab, nursing care, and medicine delivery services across 15 cities.

In line with its commitment to social responsibility, Max Healthcare provided free treatment to approximately 40,000 economically weaker patients in OPD and 1,568 in IPD, totaling ~₹61 crore at hospital tariff. This initiative underscores the company's dedication to serving the community alongside its commercial objectives. The company's focus on clinical excellence is further highlighted by successful complex surgeries and a strong research and academic pipeline, including numerous publications and ongoing clinical trials.

Outlook and Future Trajectory

Looking ahead, Max Healthcare is well-positioned for sustained growth. The full restoration of cashless services, the expected full implementation of upward revised CGHS tariffs by April 2026, and the continuous commissioning of margin-accretive incremental capacity are anticipated to drive future performance. The company's disciplined capital allocation, evidenced by its low net debt-to-EBITDA ratio (less than 1) and deployment of free cash flows towards expansion, provides a strong foundation for future growth. Max Healthcare's strategic clarity, operational excellence, and commitment to patient care position it favorably to capitalize on the growing demand for quality healthcare services in India.